Titan Medical Inc. ("the Company") (TSX VENTURE: TMD)(OTCQX: TITXF)
announced that today the Company's common shares commenced trading on
the international tier of the OTCQX market in the United States under
the ticker symbol "TITXF".
Investors can find current financial disclosure and Real-Time Level 2
quotes for the Company on www.otcqx.com(http://www.otcqx.com) and
"We are pleased to be listed on the OTCQX market, which will provide
our current and potential investors in the U.S. with a better platform
to access our company's securities," said Craig Leon, Chief Executive
Officer of Titan Medical, Inc. "As we continue to execute our growth
strategy, the OTCQX listing will help us increase Titan's awareness
among the investment community in the U.S."
Dorsey & Whitney LLP will serve as the Company's Principal American
Liaison on OTCQX, responsible for providing guidance on OTCQX
requirements and U.S. securities laws.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the world's largest
electronic marketplace for broker-dealers to trade unlisted stocks.
Its OTC Link platform supports an open network of competing
broker-dealers that provide investors with the best prices in over
10,000 OTC securities. It categorizes the wide spectrum of OTC-traded
companies into three tiers - OTCQX (the intelligent marketplace),
OTCQB@ (the venture marketplace), and OTC Pink (the open marketplace)
- so investors can identify the level and quality of information
companies provide. To learn more about how OTC Markets Group makes the
unlisted markets more transparent, informed, and efficient, visit
About Titan Medical Inc.
Titan Medical Inc. is a Canadian public company (TSX VENTURE:
TMD)(OTCQX: TITXF) focused on the development and commercialization of
robotic surgical technologies. The Company is currently developing
Amadeus Composer, a surgical system that has a uniquely designed
external robot and flexible instruments, with the objective of
allowing surgeons to overcome constraints of surgical procedures in
small to medium spaces. Amadeus Maestro, the Company's next
generation 4-armed robotic surgical system with advanced communication
and training, utilizes the Titan True Touch Technology and is targeted
to surgical procedures in large spaces. Robotic surgery has developed
over the past 10 years into a proven and growing method of treatment.
The global robotic surgical market size is currently estimated to be
approximately $1 billion and is estimated to grow to $5 billion by
2015 with potential for placement of 6,000 robotic surgical systems.
The Company is researching and developing innovative technologies to
empower surgeons to use robots in the operating room of the future.
For more information, visit the Company's website at
Forward Looking Statements
This news release contains "forward-looking statements" which reflect
the current expectations of management of the Company's future growth,
results of operations, performance and business prospects and
opportunities. Wherever possible, words such as "may", "would",
"could", "will", "anticipate", "believe", "plan", "expect", "intend",
"estimate", "potential for" and similar expressions have been used to
identify these forward-looking statements. These statements reflect
management's current beliefs with respect to future events and are
based on information currently available to management.
Forward-looking statements involve significant risks, uncertainties
and assumptions. Many factors could cause the Company's actual
results, performance or achievements to be materially different from
any future results, performance or achievements that may be expressed
or implied by such forward-looking statements, including, without
limitation, those listed in the "Risk Factors" section of the
Company's Annual Information Form dated March 31, 2011 (which may be
viewed at www.sedar.com(http://www.sedar.com)). Should one or more of
these risks or uncertainties materialize, or should assumptions
underlying the forward looking statements prove incorrect, actual
results, performance or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. These factors should be considered carefully and
prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in the news release are based upon what management currently
believes to be reasonable assumptions, the Company cannot assure
prospective investors that actual results, performance or achievements
will be consistent with these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.